
The study found that hepatic impairment reduces linezolid metabolism, increasing drug exposure. Renal failure further elevates linezolid and metabolite levels via reduced metabolism and filtration. No tissue accumulation or transporter-mediated effects were observed. These results underscore the need to adjust linezolid dosing in patients with liver or kidney dysfunction.
Like
Save
Share